Last updated: February 16, 2026
Overview
NDC 71376-0202 corresponds to a branded pre-filled syringe formulation of Risperdal Consta (risperidone long-acting injectable). This antipsychotic medication is indicated for schizophrenia and bipolar disorder. The drug is marketed by Johnson & Johnson under the Janssen division, with patent exclusivity initially expiring in 2023, though biosimilar and generic competition may influence the market landscape.
Market Size and Demand Drivers
The US schizophrenia market was valued at approximately $4.2 billion in 2022, with Risperdal Consta holding an estimated 20% share. The bipolar disorder segment contributed an additional $2.1 billion, with risperidone formulations capturing a significant portion of this.
Key factors influencing demand include:
- Increased diagnosis rates of schizophrenia and bipolar disorder.
- Growing preference for long-acting injectables (LAIs) due to improved adherence.
- Coverage policies favoring LAIs for chronic conditions.
- Patent exclusivity lapses for branded formulations leading to generic uptake.
Competitive Landscape
- Branded Risperdal Consta: Revenue peaked at over $1.2 billion annually before patent expiry.
- Generics: Multiple risperidone generics entered the market post-2023, reducing prices by 40-60%.
- Biosimilars: No biosimilar risperdal has entered yet; biosimilar development is ongoing.
Pricing Trends
- Pre-Patent Expiry: The average wholesale price (AWP) for Risperdal Consta was approximately $950 per syringe (single-dose), with actual negotiated prices significantly lower.
- Post-Patent Expiry: Generic risperidone injections entered the market, reducing the average patient cost to $350–$450 per dose.
- Market shifts: branded prices have declined by approximately 35%, with generics gaining a 60% market share by 2024.
Price Projections (2024–2028)
| Year |
Estimated Average Wholesale Price (per syringe) |
Notes |
| 2024 |
$300–$400 |
Increased generic competition drives prices downward. |
| 2025 |
$250–$350 |
Price stabilization as formulary preferences favor generics. |
| 2026 |
$220–$300 |
Further price reduction; biosimilar impact likely minimal. |
| 2027 |
$200–$280 |
Continued decline; market consolidation around generics. |
| 2028 |
$180–$260 |
Prices plateau as market stabilizes around low-cost options. |
Pricing Dynamics Factors
- Patent litigation outcomes influence generic market entry timelines.
- Formulary decisions heavily favor generic risperidone formulations.
- Reimbursement policies increasingly favor cost-effective options.
- Patient adherence programs promote LAIs, potentially moderating price erosion.
Implications for Stakeholders
- Manufacturers: price erosion suggests strategic shifts to biosimilar or new formulation development.
- Investors: peak revenues for branded Risperdal Consta likely occurred before patent expiry; future revenues depend on biosimilar market penetration.
- Healthcare providers: shifting toward more affordable generics may impact prescribing patterns.
Key Takeaways
- The market for NDC 71376-0202 transitioned from branded dominance to generics post-2023.
- Prices declined sharply after patent expiration, with further reductions projected over the next five years.
- Current average wholesale prices are estimated between $180 and $400 per syringe.
- Biosimilar entry remains limited, but market dynamics favor cost-based competition.
- Pricing and access will be heavily influenced by formulary decisions, reimbursement policies, and patent litigation outcomes.
FAQs
-
Will the price of NDC 71376-0202 rise again?
No. After patent expiration, prices are projected to decline or stabilize at low levels unless new formulations or biosimilars enter the market.
-
How does biosimilar development impact the market?
Biosimilars could further reduce prices but are not yet available for risperidone injectables, potentially delaying price erosion in the near term.
-
What factors influence the adoption of generics over branded risperdal?
Cost savings, formulary priorities, and provider preference for more affordable options drive the shift.
-
Are there any recent patent litigations affecting this drug?
Patent disputes concluded by 2024 cleared the way for generic competition; ongoing patent challenges may influence future exclusivity.
-
What is the outlook for patient access to risperidone LAI?
Prices falling below $250 per dose improve access, especially where insurance mandates generic prescriptions for cost savings.
Sources
[1] IQVIA, 2022 Market Reports
[2] FDA Patent and Exclusivity Data
[3] J&J Annual Reports, 2022
[4] Medicare Part D Formularies, 2023
[5] Industry Price Trends, 2023–2024
